Adaptimmune Launches Tecelra as a New Hope for Synovial Sarcoma
Adaptimmune Therapeutics PLC, a leading player in T-cell therapy for cancer, has announced the launch of Tecelra, its pioneering engineered cell therapy product. This significant milestone arrives as the first new treatment option for synovial sarcoma in over a decade, highlighting the company's commitment to advancing cancer treatment.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
